Valuation : Soleno Therapeutics, Inc.

Market Cap 2.76B 2.38B 2.25B 2.04B 3.82B 264B 3.86B 26.72B 10.28B 134B 10.37B 10.15B 427B P/E 2024
-10.3x
P/E 2025 119x
Enterprise Value 2.31B 1.99B 1.88B 1.71B 3.19B 220B 3.23B 22.33B 8.59B 112B 8.67B 8.48B 356B EV / Sales 2024
-
EV / Sales 2025 10,678,497x
Free-Float
98.88%
Yield 2024 *
-
Yield 2025 -
1 day+0.04%
6 months+33.29%
Current year+14.49%
Current year 29.43
Extreme 29.43
53.01
1 year 29.43
Extreme 29.43
72.88
3 years 3.82
Extreme 3.82
90.32
5 years 0.85
Extreme 0.85
90.32
10 years 0.85
Extreme 0.85
99
Manager TitleAgeSince
President 61 2026-05-14
Treasurer 46 2026-05-14
Director TitleAgeSince
Director/Board Member 61 2026-05-14
Director/Board Member 46 2026-05-14
Date Insider Type Main position Quantity % Market Cap. Importance
5/18/26 Issuer sale

Director

-16,991 0.0329%
5/18/26 Issuer sale

SEE REMARKS

-150,284 0.2911%
5/18/26 Issuer sale

Director

-19,554 0.0379%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%-.--%-24.50%+1,259.23% 2.76B
-0.25%-0.96%+45.25%+102.76% 68.52B
-1.09%-4.97%+31.10%+76.56% 62.88B
-1.18%+0.51%-13.53%+384.69% 28.13B
-2.74%-3.53%+26.13%+13.50% 25.56B
-1.76%-7.14%-5.57%-19.75% 24.65B
-2.39%-4.23%+18.42%-20.95% 19.81B
-1.86%+1.15%+205.44%+353.89% 17.69B
-1.37%-3.77%-9.38%+528.34% 14.66B
-1.54%-1.88%+50.03%+159.75% 14.45B
Average -1.41%-1.19%+32.34%+283.80% 27.91B
Weighted average by Cap. -1.27%-1.39%+34.83%+150.16%

Financials

2024 2025
Net sales - 190.4 164 154.79 140.92 263.41 18.17K 265.93 1.84K 708.42 9.25K 714.97 699.32 29.39K
Net income -176M -151M -143M -130M -243M -16.78B -246M -1.7B -654M -8.54B -660M -646M -27.15B 20.89M 17.99M 16.98M 15.46M 28.9M 1.99B 29.18M 202M 77.72M 1.01B 78.44M 76.72M 3.22B
Net Debt -266M -229M -216M -197M -368M -25.37B -371M -2.57B -989M -12.91B -998M -976M -41.03B -454M -391M -369M -336M -627M -43.29B -633M -4.39B -1.69B -22.02B -1.7B -1.67B -70.01B
Logo Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder. The Company sells its product primarily to a specialty pharmacy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
  1. Stock Market
  2. Stocks
  3. SLNO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!